JC02 Rec'd PCT/PTC

2005 PCT

PATENT APPLICATION

THE LATTED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: O85692

HABASHITA, Hiromu, et al. Appln. No.: 10/520,660

Group Art Unit: Not yet assigned

Confirmation No.: Not yet assigned

Examiner: Not yet assigned

Filed: January 10, 2005

For: CCR4 ANTAGONIST AND MEDICAL USE THEREOF

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby supplements the Information Disclosure Statement filed on January 10, 2005. That IDS listed five documents, as well as the corresponding International Search Report. However, copies of the documents were not provided at the time of the filing of the IDS. We now enclose for your convenience copies of the same.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under \$1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.: 10/520,660

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,

Registration No. 32,197

SUGHRUE MION, PLLC Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE 23373
CUSTOMER NUMBER

Date: May 19, 2005

INTERNATIONAL SEARCH REPORT

International application No. PCT/JP03/08654

A CLASSIFICATION OF SUBJECT MATTER 1nt. Cl. COTD241/22, A61K31/4965, 31/497, 31/498, 31/506, A61P1/04, 1/16, 1/18, 3/10, 9/10, 11/00, 11/06, 13/12, 17/06, 19/02, 25/00, 27/02, 27/16, 29/00, 31/12, 31/18, 35/00, 35/02, 37/00, According to International Patent Classification (Pto to both autional dassification and PtC B FIELDS SEARCHED Minimum documentation exacthed (classification system followed by classification symbols) 1nt. Cl. COTD241/22, A61K31/4965, 31/497, 31/498, 31/506, COTD401/12, 403/12, 405/12, 409/12, 413/12, 417/12, A61K31/55 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched					
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CA(STN), REGISTRY(STN), WPIDS(STN)					
C. DOCUMENTS CONSIDERED TO BE RELEVANT					
Category* Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.				
X 7P "S-345759 A (Kaken Pharmaceutical Co.; EEG#); 27 December, 1993 (27.12.93), Claims; Par. No. [0080]; examples 5, 6 & EP 529365 A	1-3,8-12, 14-20,22-25, 27-32,34-43, 45-49 33				
X (Jr 4-257578 A (Bayer AG), 11 September, 1992 (11-03.92), Claims; Par. No. [0182], example 4 EP 473024 A	1,4,5,8-28, 30-32,34-43, 45-49				
(WO 01/45694 A (SATURKLING BEEGHAN CORE)) 28 June, 2001 (28.06.01), Pages 10, 17, 31, 6 JP 2003-518057 A	1,3,8-12, 14-20,22-25, 27-32,34-43, 45-49				
Further documents are listed in the continuation of Box C. See patent family annex.					
Special eategories of cited documents: "A" "Second eategories of cited documents: "I later document application for the part which is not considered to be of particular relevance. The considered to be of particular relevance. The considered to be of particular relevance. The document is published on or after the international filing to document to published on or after the international filing to document to published on the property of document of particular relevance, the dament diversals in tenand to confident with the publication dute of mother citation or other special reason (as specified) "O document of particular relevance, the claimed diversals in tenand to confident with the published point to the international filing date but later document of particular relevance, the claimed diversals in tenand to confident with one or more other used documents, such document of particular relevance, the claimed diversals or more other used documents, such document of particular relevance, the claimed diversals or more other used documents, such document of particular relevance, the claimed diversals or more other used documents, such document of particular relevance, the claimed diversals or more other used documents, such document of particular relevance, the claimed diversals or more other used documents, such document of particular relevance, the claimed diversals or more other used documents, such document of particular relevance, the claimed diversals or more other used documents, such documents of particular relevance, the claimed diversals or more other used documents, such documents of particular relevance, the claimed diversals or more other used to comment of particular relevance, the claimed diversals or more other used to comment of particular relevance, the claimed diversals or more other used to comment of particular relevance, the claimed diversals or more other used to comment of particular relevance, the claimed diversals or more other used to comment of particular relevance, the claimed diver					
Name and mailing address of the ISAV Japanese Patent Office					

Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP03/08654

C (Continuation),	DOCUMENTS	CONSIDERED	TORE	FLEVANT	

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
x v	00 02/20437 A (MENARINI RICERCHE)A 14 March, 2002-(14.03.02), Claims, examples 14, 15; page 33 4 AU 2002-10495 A	1-12,14-20, 35-43,45-49	
P.X	(WO 03/16254 A (One Pharmaceutical Co., Ltd.), 27 February, 2003 (27.02.03), Claims (Family: none)	1-43,45-49	
	6		
	,		
	*		
8			
-			

Form PCT/ISA/210 (continuation of second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP03/08654

Box ! Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)	
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reason	ns:
1. X Claims Nos.: 44	
because they relate to subject matter not required to be searched by this Authority, namely: Claim 44 pertains to a method for treatment of the human body by therap	ру.
 X Claims Nos.: 1-32, 34-43, and .45-49 because they relate to parts of the international application that do not comply with the prescribed requirements to such extent that no meaningful international search can be carried out, specifically: (See extra sheet) 	an
Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).	
Box II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)	
This International Searching Authority found multiple inventions in this international application, as follows:	
As all required additional search fees were timely paid by the applicant, this international search report covers all search claims.	ible
 As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payme of any additional fee. 	nt
 As only some of the required additional search fees were timely paid by the applicant, this international search report co- only those claims for which fees were paid, specifically claims Nos.: 	ers
 No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 	
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.	

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1998)

INTERNAT SAL SEARCH REPORT

Internations plication No.
PCT/JP03/08654

Continuation of A. CLASSIFICATION OF SUBJECT MATTER

(International Patent Classification (IPC))

Int.Cl⁷ 37/06, 37/08, 43/

37/06, 37/08, 43/00, 17/00, C07D401/12, 403/12, 405/12, 409/12, 413/12, 417/12, A61K31/55

(According to International Patent Classification (IPC) or to both national classification and IPC)

Continuation of Box No.I-2 of continuation of first sheet(1)

The subject matters of claims 1-32, 34-43, and 45-49 are a compound represented by the general formula (I), a medicinal composition containing the compound as an active ingredient, etc. However, the compound involves an extremely wide range of various compounds. It is hence difficult to make a complete search for all of them. On the other hand, the compounds which are supported by the description in the meaning of Article 6 of the PCT and are disclosed in the description in the meaning of Article 5 of the PCT are limited to an extremely small part of the compounds. Consequently, claims 1-32, 34-43, and 45-49 and the description do

Consequently, claims 1-32, 34-43, and 45-49 and the description do not comply with the given requirements to such a degree that a meaningful international search can be made.

The term "prodrug" used in the claims is unclear as to what structure is implied, even when the statements in the description are investigated. This term hence makes the scope of the compounds and medicines of the invention unclear.

In this international search report, a search with respect to claims 1-32, 34-43, and 45-49 was hence made for the compounds specified in the description through prior art documents within the range of a reasonable burden.

Form PCT/ISA/210 (extra sheet) (July 1998)